Cargando…

Phase I clinical trial of nintedanib plus paclitaxel in early HER-2-negative breast cancer (CNIO-BR-01-2010/GEICAM-2010-10 study)

INTRODUCTION: Previous small-molecule antiangiogenics have compromised chemotherapy dose intensity in breast cancer. We present a phase I trial of a novel selective agent, nintedanib, plus standard chemotherapy in early breast cancer. METHODS: Her-2-negative breast cancer patients with tumours large...

Descripción completa

Detalles Bibliográficos
Autores principales:	Quintela-Fandino, M, Urruticoechea, A, Guerra, J, Gil, M, Gonzalez-Martin, A, Marquez, R, Hernandez-Agudo, E, Rodriguez-Martin, C, Gil-Martin, M, Bratos, R, Escudero, M J, Vlassak, S, Hilberg, F, Colomer, R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2014
Materias:	Short Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4453846/ https://www.ncbi.nlm.nih.gov/pubmed/25058346 http://dx.doi.org/10.1038/bjc.2014.397

Ejemplares similares

A phase I study of the SRC kinase inhibitor dasatinib with trastuzumab and paclitaxel as first line therapy for patients with HER2-overexpressing advanced breast cancer. GEICAM/2010-04 study
por: Ocana, Alberto, et al.
Publicado: (2017)

Recomendación 01/2010 : cortesía judicial.
Publicado: (2010)

Pension Fund - Actuarial review as at 01.01.2010
Publicado: (2010)

Nintedanib plus letrozole in early breast cancer: a phase 0/I pharmacodynamic, pharmacokinetic, and safety clinical trial of combined FGFR1 and aromatase inhibition
por: Quintela-Fandino, Miguel, et al.
Publicado: (2019)

Summary Session 01 : Review of 2010 Operations
por: Meddahi, Malika, et al.
Publicado: (2011)

BOMET-QoL-10 questionnaire for breast cancer patients with bone metastasis: the prospective MABOMET GEICAM study
por: Barnadas, A., et al.
Publicado: (2019)

Nintedanib selectively inhibits the activation and tumour-promoting effects of fibroblasts from lung adenocarcinoma patients
por: Gabasa, M, et al.
Publicado: (2017)

Primary breast cancer and health related quality of life in Spanish women: The EpiGEICAM case-control study
por: Fernández de Larrea-Baz, Nerea, et al.
Publicado: (2020)

Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01)
por: Lluch, Ana, et al.
Publicado: (2020)

Survival impact of primary tumor resection in de novo metastatic breast cancer patients (GEICAM/El Alamo Registry)
por: Lopez-Tarruella, Sara, et al.
Publicado: (2019)

GEICAM Guidelines for the Management of Patients with Breast Cancer During the COVID‐19 Pandemic in Spain
por: Martin, Miguel, et al.
Publicado: (2020)

Spanish Mediterranean diet and other dietary patterns and breast cancer risk: case–control EpiGEICAM study
por: Castelló, A, et al.
Publicado: (2014)

SEOM–GEICAM–SOLTI clinical guidelines in advanced breast cancer (2022)
por: Garcia-Saenz, Jose Angel, et al.
Publicado: (2023)

Response to Moore and others (2010) and Mehta (2010)
por: Cohen, Adam L., et al.
Publicado: (2011)

Frequency of breast cancer with hereditary risk features in Spain: Analysis from GEICAM “El Álamo III” retrospective study
por: Márquez-Rodas, Iván, et al.
Publicado: (2017)

Correction to: SEOM–GEICAM–SOLTI clinical guidelines in advanced breast cancer (2022)
por: Garcia-Saenz, Jose Angel, et al.
Publicado: (2023)

SEOM-GEICAM-SOLTI clinical guidelines for early-stage breast cancer (2022)
por: Ayala de la Peña, Francisco, et al.
Publicado: (2023)

Pembrolizumab in combination with gemcitabine for patients with HER2-negative advanced breast cancer: GEICAM/2015–04 (PANGEA-Breast) study
por: de la Cruz-Merino, L., et al.
Publicado: (2022)

Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: results from the GEICAM/2006-14 trial
por: Alba, E, et al.
Publicado: (2014)

Thyroid function alters during neoadjuvant chemotherapy in breast cancer patients: results from the NEOZOTAC trial (BOOG 2010-01)
por: de Groot, S., et al.
Publicado: (2015)

BE Department Annual Report 2010
por: Bruning, O, et al.
Publicado: (2011)

BOOST2010 Workshop
por: Karagoz, M, et al.
Publicado: (2010)

Professional Team Foundation Server 2010
por: Blankenship, Ed, et al.
Publicado: (2011)

2010 commissioning plans
por: Lamont, M
Publicado: (2010)

Office 2010 Bible
por: Walkenbach, John, et al.
Publicado: (2010)

Illustrated C# 2010
por: Solis, Daniel M
Publicado: (2010)

C# 2010 for programmers
por: Deitel, Paul J, et al.
Publicado: (2011)

Enhancing gastric cancer conventional chemotherapy effects by triple angiokinase inhibitor nintedanib in preclinical models
por: Awasthi, Niranjan, et al.
Publicado: (2023)

Cancers in Australia in 2010 attributable to tobacco smoke
por: Pandeya, Nirmala, et al.
Publicado: (2015)

Nomenclature for factors of the HLA system, 2010
por: Marsh, S G E, et al.
Publicado: (2010)

Nintedanib for the treatment of patients with refractory metastatic colorectal cancer (LUME-Colon 1): a phase III, international, randomized, placebo-controlled study
por: Van Cutsem, E, et al.
Publicado: (2018)

Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume
por: Kolb, Martin, et al.
Publicado: (2017)

Controversies in Breast Cancer 2010
por: Miller, William R
Publicado: (2010)

SharePoint 2010 development with Visual Studio 2010
por: Carter, Eric, et al.
Publicado: (2011)

ESICM 2010 MONDAY SESSIONS 11 October 2010
Publicado: (2010)

ESICM 2010 WEDNESDAY SESSIONS 13 October 2010
Publicado: (2010)

ESICM 2010 TUESDAY SESSIONS 12 October 2010
Publicado: (2010)

Beam parameters and machine performance to be reached in 2010
por: Assmann, R, et al.
Publicado: (2010)

Contributions to Research at ISOLDE in 2010
por: Andreyev, A, et al.
Publicado: (2011)

Bullous pemphigoid associated with nintedanib
por: Hasson, Amelia M., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_0bjvgmjq0ate5ub6bcurckh8he